ARTICLE | Company News
Orexo, AstraZeneca deal
April 4, 2016 7:00 AM UTC
AstraZeneca exercised a 2013 option to license exclusive, worldwide rights to Orexo’s OX-CLI program. The leukotriene C4 synthase (LTC4S) inhibitor is in preclinical development to treat respiratory...